View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 20, 2020

Novartis to study hydroxychloroquine for Covid-19

Novartis has entered an agreement with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of hydroxychloroquine to treat hospitalised patients with Covid-19.

Hydroxychloroquine, which is commonly used to treat malaria and some autoimmune diseases, showed anti-SARS-CoV-2 activity in laboratory tests.

Sponsored by Novartis, the new Phase III trial will assess hydroxychloroquine as a potential Covid-19 therapy in around 440 participants.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena